PTM Oral LEN

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

9 competitors in Pre-Exposure Prophylaxis of HIV Infection

#DrugCompanyPhaseTrials

1

Sunlenca

Gilead

Phase 3

32

PTM SEMA

Gilead

Phase 3

13

F/TAF

Gilead

Phase 3

14

F/TDF

Gilead

Phase 3

35

PTM Oral LEN

Gilead

Phase 3

16

Emtricitabine/tenofovir Alafenamide

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 2

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pre-Exposure Prophylaxis of HIV Infection1 trial

A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruiting·Gilead·Phase 3·NCT04994509·5,368 enrolled

Details

Drug Info

Related News